Department of Political Science, Oklahoma State University, 210 Social Science & Humanities Hall, Stillwater, OK, 74078, USA.
Soc Sci Med. 2021 Mar;272:113642. doi: 10.1016/j.socscimed.2020.113642. Epub 2021 Jan 4.
A vaccine for the novel coronavirus (COVID-19) could prove critical in establishing herd immunity. While past work has documented the prevalence and correlates of vaccine refusal, I assess how a less explored topic -- properties of vaccines themselves (e.g., national origin, efficacy, risk of side effects) -- might influence vaccination intentions. This information can help public health officials preempt differential intentions to vaccinate, and inform health communication campaigns that encourage vaccine uptake.
Previous research suggests that Americans should be more likely to intend to vaccinate if presented with a US-made vaccine that carries a low risk of minor side effects, is highly effective, is administered in just one dose, and has spent significant time in development.
I administered a conjoint experiment (N = 5940 trials) in a demographically representative survey (N = 990) of US adults to assess how variation in vaccine properties influence self-reported public vaccination intentions.
I find that respondents prefer vaccines that are US-made, over 90% effective, and carry a less than 1% risk of minor side effects. This is potentially problematic, as some leading vaccine candidates are produced outside the US, and/or may be more likely to produce minor side effects than respondents would otherwise prefer. Worryingly, intended vaccine refusal rates exceed 30% for a vaccine meeting these optimal characteristics. Encouragingly, though, Americans show no clear preference for vaccines administered in one dose, or developed in under a year, and do not appear to draw a distinction between weakened viral vs. mRNA-based vaccines.
Americans' preferences for a novel coronavirus vaccine may be at odds with the vaccine that ultimately hits the market, posing both policy and health communication challenges for vaccination uptake.
新型冠状病毒(COVID-19)疫苗的研发可能对建立群体免疫至关重要。虽然过去的研究已经记录了疫苗接种拒绝率的流行率和相关因素,但我评估了一个较少被探讨的话题——疫苗本身的特性(例如,原产国、功效、副作用风险)——如何影响接种意愿。这些信息可以帮助公共卫生官员预测不同的接种意愿,并为鼓励疫苗接种的健康传播活动提供信息。
先前的研究表明,如果美国制造的疫苗具有以下特性,即副作用风险低、高度有效、只需一剂、经过大量开发时间,美国人更有可能打算接种疫苗:美国人应该更有可能打算接种疫苗:美国人应该更有可能打算接种疫苗。
我在美国成年人中进行了一项具有代表性的调查(N=990)中的联合实验(N=5940 次试验),以评估疫苗特性的变化如何影响自我报告的公众接种意愿。
我发现,受访者更喜欢美国制造、有效率超过 90%且副作用风险低于 1%的疫苗。这可能是一个问题,因为一些领先的疫苗候选者是在美国境外生产的,或者可能比受访者希望的更容易产生轻微的副作用。令人担忧的是,对于符合这些最佳特征的疫苗,预计拒绝接种的比例超过 30%。不过,令人鼓舞的是,美国人对一剂接种或在不到一年时间内开发的疫苗没有明显偏好,并且似乎没有区分弱化病毒与基于 mRNA 的疫苗。
美国人对新型冠状病毒疫苗的偏好可能与最终上市的疫苗不符,这对疫苗接种率的提高提出了政策和健康传播方面的挑战。